β2-Microglobulin and Phosphate Clearances Using a Wearable Artificial Kidney: A Pilot Study

American Journal of Kidney Diseases

Volumn 54, Issue 1, 2009, Pages 104-111

  Gura, Victor ^a,b   Davenport, Andrew ^c   Beizai, Masoud ^b   Ezon, Carlos ^b   Ronco, Claudio ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Xcorporeal Inc   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

2 microglobulin; Chronic kidney disease; clearances; hemodialysis; phosphate; wearable artificial kidney

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; PHOSPHATE; UREA;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSATE; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; MALE; MOLECULE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PILOT STUDY; PROTEIN BLOOD LEVEL; UREA BLOOD LEVEL; BLOOD; CHRONIC DISEASE; KIDNEY DISEASE; MIDDLE AGED;

ADULT; AGED; BETA 2-MICROGLOBULIN; CHRONIC DISEASE; CREATININE; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY, ARTIFICIAL; MALE; MIDDLE AGED; PHOSPHATES; PILOT PROJECTS; UREA;

EID: 67449141668     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.02.006     Document Type: Article

References (36)

1. Gotch F.A., and Sargent J.A. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28 (1985) 526-534
2. Kalantar-Zadeh K., Kovesdy C.P., Derose S.F., Horwich T.B., and Fonarow G.C. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol 3 (2007) 493-506
3. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002) 2010-2019
4. Spalding E.M., Chandna S.M., Davenport A., and Farrington K. Kt/V underestimates the hemodialysis dose in women and small men. Kidney Int 74 (2008) 348-355
5. Vanholder R., De Smet R., Glorieux G., et al., European Uremic Toxin Work Group (EUTox). Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63 (2003) 1934-1943
6. Pickett T.M., Cruickshank A., Greenwood R.N., Taube D., Davenport A., and Farrington K. Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients. Blood Purif 20 (2002) 161-166
7. 2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 69 (2006) 1431-1437
8. 2-microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 17 (2006) 546-555
9. Locatelli F., Manzoni C., and Di Filippo S. The importance of convective transport. Kidney Int Suppl 80 (2002) S115-S120
10. Canaud B., Bragg-Gresham J.L., Marshall M.R., et al. Patients receiving hemodiafiltration or hemofiltration have lower mortality risk than patients receiving hemodialysis without replacement fluid (HD) in Europe: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14 (2003) 31A (abstr)
11. Jirka T., Cesare S., Di Benedetto A., Perera Chang M., Ponce P., and Richards N. The impact of on-line haemodiafiltration (HDF) on patient survival: Results from a large network database. Nephrol Dial Transplant 20 suppl 5 (2005) S18-S19
12. 2-Microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 15 (2000) 58-64
13. 2-microglobulin and phosphate during hemodialysis: Effects of treatment frequency and duration. Semin Dial 18 (2005) 401-408
14. Sugisaki H., Onohara M., and Kunitomo T. Dynamic behavior of plasma phosphate in chronic dialysis patients. Trans Am Soc Artif Intern Organs 28 (1982) 302-307
15. Spalding E.M., Chamney P.W., and Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int 61 (2001) 655-657
16. Minutolo R., Bellizzi V., Cioffi M., et al. Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights. J Am Soc Nephrol 13 (2002) 1046-1054
17. Pieratos A., Owendyk M., Francoeur R., et al. Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol 9 (1998) 859-868
18. Toussaint N., Boddington J., Simmonds R., Waldron C., Somerville C., and Agar J. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial Int 10 (2006) 280-286
19. Gura V., Beizai M., Ezon C., and Polaschegg H.D. The wearable artificial kidney (WAK). Contrib Nephrol 149 (2005) 325-333
20. Gura V., Beizai M., and Ezon C. CRRT for CHF; The wearable continuous ultrafiltration system. ASAIO J 52 (2006) 59-61
21. Gura V., Ronco C., Nalesso F., et al. A wearable hemofilter: First human study of slow continuous ambulatory ultrafiltration. Kidney Int 74 (2008) 497-502
22. Davenport A., Gura V., Ronco C., Beizai M., Ezon C., and Rambod E. A wearable haemodialysis device for patients with end-stage renal failure: A pilot study. Lancet 370 (2007) 2005-2010
23. Davenport A. Anticoagulation options for intermittent haemodialysis. Minerva Urol Nefrol 58 (2006) 171-180
24. Gura V., Beizai M., Ezon C., Snukal R., and Rambod E. The wearable artificial kidney (WAK) removes beta2-microglobulins (B2M). J Am Soc Nephrol 17 (2006) 723A-724A (abstr)
25. Davenport A., Will E.J., and Davison A.M. Effect of the direction of dialysate flow on the efficiency of continuous arteriovenous haemodialysis. Blood Purif 8 (1990) 329-336
26. Brunet S., Leblanc M., Geadah D., Parent D., Courteau S., and Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 34 (1999) 486-492
27. Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int Suppl 60 (2004) S25-S32
28. Morey B., Walker R., and Davenport A. More dietetic time, better outcome?. A randomized prospective study investigating the effect of more dietetic time on phosphate control in end-stage kidney failure haemodialysis patients. Nephron Clin Pract 109 (2008) c173-c180
29. Block G.A., Hulbert-Shearon T.E., Levin N.W., and Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31 (1998) 607-617
30. Ayus J.C., Mizani M.R., Achinger S.G., Thadhani R., Go A.S., and Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol 16 (2005) 2778-2788
31. Mucsi I., Hercz G., Uldall R., Ouwendyk M., Francoeur R., and Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53 (1998) 1399-1404
32. Davenport A., Will E.J., and Davison A.M. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 41 (1993) S245-S251
33. Coburn J.W., Hartenbower D.L., Brickman A.S., et al. Intestinal absorption of calcium, magnesium and phosphorus in chronic renal insufficiency. In: David D.S. (Ed). Calcium and Metabolism in Renal Failure and Nephrolithiasis (1977), Wiley, New York, NY 77-109
34. Ramirez J.A., Emmett M., and White M.G. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30 (1986) 753-759
35. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 30 suppl 4 (1997) S20-S27
36. Davenport A. The management of heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int 3 (2001) 81-85